Let's spread the word about Immunotherapy! Click to share this page with your community.

Methodology for Combinations with ICIs & Moving to Novel Therapeutics

Vanessa M. Lucey, Ph.D., MBA, director of CRI Clinical Accelerator and Venture Fund, is presenting at the Methodology for Combinations with ICIs and Moving to Novel Therapeutics (MDICT) task force meeting on Sunday, March 1, 2020, at 6:00 p.m.

MDICT is a side meeting before ESMO Targeted Anticancer Therapies Congress 2020. The MDICT task force was established by the New Drug Development Office (NDDO) Research Foundation in 2006 to provide advice on the development of novel anticancer agents. MDICT has been supported by ESMO since 2018. Speakers at the ESMO Targeted Anticancer Therapies meeting are usually invited. The task force has published a number of recommendations. 

The NDDO Research Foundation aims at stimulating improvements in cancer treatment by enhancing the development and introduction into daily practice of new therapies. This aim is pursued by the conduct of research projects and the organization of scientific meetings. 

*Immunotherapy results may vary from patient to patient.